BridgeBio Pharma, Inc. Common Stock BBIO
i
Market dataready · fetched 2026-11-13T19:12:13.256Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:11:53.318497666Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T19:12:12.768038+00:00
BridgeBio Pharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 83.37 | 48.4% | 7.0% | 73.58 | 56.9% | 7.1% |
| 25Δ | 82.14 | 45.7% | 5.6% | 75.15 | 48.8% | 5.2% |
| 30Δ | 81.41 | 46.0% | 5.0% | 75.89 | 48.3% | 4.6% |
| 35Δ | 80.68 | 46.3% | 4.3% | 76.63 | 47.9% | 4.0% |
| 40Δ | 79.96 | 46.5% | 3.7% | 77.36 | 47.4% | 3.3% |
| 45Δ | 79.32 | 46.4% | 3.3% | 78.02 | 47.1% | 2.9% |
| 50Δ | 78.68 | 46.3% | 2.8% | 78.66 | 46.7% | 2.5% |
| 55Δ | 78.04 | 46.2% | 2.4% | 79.30 | 46.4% | 2.1% |
| 60Δ | 77.40 | 46.0% | 2.0% | 79.95 | 46.1% | 1.7% |
| 65Δ | 76.75 | 45.3% | 1.7% | 80.76 | 47.1% | 1.4% |
| 70Δ | 76.10 | 44.7% | 1.4% | 81.59 | 48.3% | 1.2% |
| 75Δ | 75.45 | 44.0% | 1.0% | 82.42 | 49.4% | 0.9% |
| 80Δ | 74.41 | 46.8% | 0.8% | 83.74 | 51.9% | 0.7% |
20Δ
- Pseudo strike
- 83.37
- IV
- 48.4%
- B/E move
- 7.0%
- Pseudo strike
- 73.58
- IV
- 56.9%
- B/E move
- 7.1%
25Δ
- Pseudo strike
- 82.14
- IV
- 45.7%
- B/E move
- 5.6%
- Pseudo strike
- 75.15
- IV
- 48.8%
- B/E move
- 5.2%
30Δ
- Pseudo strike
- 81.41
- IV
- 46.0%
- B/E move
- 5.0%
- Pseudo strike
- 75.89
- IV
- 48.3%
- B/E move
- 4.6%
35Δ
- Pseudo strike
- 80.68
- IV
- 46.3%
- B/E move
- 4.3%
- Pseudo strike
- 76.63
- IV
- 47.9%
- B/E move
- 4.0%
40Δ
- Pseudo strike
- 79.96
- IV
- 46.5%
- B/E move
- 3.7%
- Pseudo strike
- 77.36
- IV
- 47.4%
- B/E move
- 3.3%
45Δ
- Pseudo strike
- 79.32
- IV
- 46.4%
- B/E move
- 3.3%
- Pseudo strike
- 78.02
- IV
- 47.1%
- B/E move
- 2.9%
50Δ
- Pseudo strike
- 78.68
- IV
- 46.3%
- B/E move
- 2.8%
- Pseudo strike
- 78.66
- IV
- 46.7%
- B/E move
- 2.5%
55Δ
- Pseudo strike
- 78.04
- IV
- 46.2%
- B/E move
- 2.4%
- Pseudo strike
- 79.30
- IV
- 46.4%
- B/E move
- 2.1%
60Δ
- Pseudo strike
- 77.40
- IV
- 46.0%
- B/E move
- 2.0%
- Pseudo strike
- 79.95
- IV
- 46.1%
- B/E move
- 1.7%
65Δ
- Pseudo strike
- 76.75
- IV
- 45.3%
- B/E move
- 1.7%
- Pseudo strike
- 80.76
- IV
- 47.1%
- B/E move
- 1.4%
70Δ
- Pseudo strike
- 76.10
- IV
- 44.7%
- B/E move
- 1.4%
- Pseudo strike
- 81.59
- IV
- 48.3%
- B/E move
- 1.2%
75Δ
- Pseudo strike
- 75.45
- IV
- 44.0%
- B/E move
- 1.0%
- Pseudo strike
- 82.42
- IV
- 49.4%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- 74.41
- IV
- 46.8%
- B/E move
- 0.8%
- Pseudo strike
- 83.74
- IV
- 51.9%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 49.63% | |
| 49.10% | |
| 49.59% | |
| 49.45% | |
| 49.50% | |
| 48.69% | |
| 49.09% | |
| 48.37% | |
| 49.90% | |
| 45.77% |
Biotechnology
BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
More →BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is…
More →BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
More →BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in…
More →BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The…
More →BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular…
More →